An update on the treatment of patients with mCRPC with RA-223 plus AAP
An update on the treatment of patients with mCRPC with RA-223 plus AAP
Prof. Tia Higano
Dr Tia Higano provides her perspective on ERA 223: A phase 3 trial of Ra-223 in combination with AAP in the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve patients with bone-predominant mCRPC
Prof. Tia Higano
Medical Oncologist
University of British Columbia
United States (US)
| 
5 min
|
Oct 2021
download resources
This programme was made for you: your opinion matters
Share your feedback in just 4 clicks and help us to continue to create the content you need.
I agree that this educational programme:
An update on the treatment of patients with mCRPC with RA-223 plus AAP
Dr Tia Higano comments on the results of ERA223, a phase 3 trial that evaluated concurrent treatment of radium-223 (Ra-223) and abiraterone acetate and prednisone/prednisolone (AAP). Ra-223 and AAP are tested in the treatment of asymptomatic or mildly symptomatic chemotherapy naïve patients with bone predominant metastatic castration-resistant prostate cancer (mCRPC).
Dr Higano highlights important findings that influence clinical practice. In the accompanying slide set Dr Higano presents ERA223 trial results on the primary endpoint of symptomatic skeletal event-free survival, and the secondary endpoint of overall survival. Data on frequency of fractures is examined and the effect of bone health agents. Dr Higano concludes with advice on the use of radium and bone health agents in mCRPC. The video and accompanying slides provide medical education for medical oncologists, and we hope you find it of use for your own clinical practice.
GU CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from AstraZeneca, Bayer and Eisai Europe Limited.
Other programmes of interest
27 min
